Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

The Danish company’s controlling shareholder, the Novo Nordisk Foundation, had pushed him to step down after the share price ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

The $2.2 billion deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and ...

Novo Nordisk is moving forward with plans to develop oral obesity drugs through a new partnership, which comes as longtime ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

Taking a statin medication is an effective, safe, and low-cost way to lower cholesterol and reduce risk of cardiovascular events. Despite clinicians recommending that many patients with diabetes take ...

Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...